Mark Pegram

Oncternal Oncology, Inc. is a clinical-stage oncology company, which engages in the development of novel therapies for both rare and common cancers. The company was founded by Lauren Otsuki and Cam L. Garner and is headquartered in San Diego, CA.

Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA.

MOMA Therapeutics, Inc. operates as a biotechnology firm. The company was founded by Dorothee Kern, Eva Nogales, Johannes Walter, and Timur Yusufzai and is headquartered in Cambridge, MA.

IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation.

Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA.

University of Washington functions as a College/University. The company is headquartered in Seattle, WA.

Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands.

Celsius Therapeutics, Inc. translates single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer. The company was founded by Jeffrey A. Bluestone, Vijay K. Kuchroo, Christoph S. Lengauer, Aviv Regev and Ramnik Xavier in 2018 and is headquartered in Boston, MA.

Lengo Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Menlo Park, CA.

Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA.

Solve Therapeutics, Inc. is an oncology-focused biopharmaceutical company that develops novel antibody-based therapies targeting tumor-specific antigens. The company is based in Belmont, CA, and has subsidiaries in the United States. The company's formation has reunited members of the former VelosBio Inc. team, a highly experienced group with a proven ability to rapidly advance innovative therapeutics that address unmet medical needs in the treatment of cancer. Solvetx has been actively pursuing discovery and development efforts at its state-of-the-art laboratory facilities. The company has licensed or generated targeting antibodies and nanobodies with ideal characteristics to serve as the backbones for antibody-based therapeutics and has rights to technology supporting the development of diagnostic and therapeutic antibody-radionuclide conjugates (ARCs). Solvetx is supported by a syndicate of sophisticated healthcare investors, including Ayurmaya Capital Management Fund (an affiliate of Matrix Capital Management), Decheng Capital, General, and Surveyor Capital (a Citadel company). The company was founded by David M. Johnson and has been led by him as the CEO since incorporation.

Asana BioSciences LLC is a research and development company that specializes in discovering new chemical and biological entities. The private company is based in Bridgewater, NJ. The company focuses on developing novel targeted investigational medicines in immunology/inflammation and oncology. Asana Biosciences has a list of programs in the development pipeline, including additional oncology pipeline candidates. The company was founded in 2014 by Sandeep Gupta and Chintu Patel.

Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts.

Cellular Research, Inc. operates as a biotechnology research and development company. It offer Precise assays that provides quantitation of mRNA targets in single cells and small samples; precise predefined gene expression panels; and Pixel system, a detection platform for direct mRNA quantitation from single cells and rare samples. The company’s products are used in various applications that include gene expression validation, RNA-seq validation, pathway validation, and rare transcript detection. The company was founded by Stephen P. A. Fodor, Ari Chaney, Stephen R. Quake and Glenn Fu in 2011 and is headquartered in Menlo Park, CA.

Genetic Alliance, Inc. provides health care services through genetics. Its customers include parent and family groups, community organizations, professional societies, corporations, and government agencies. The company was founded by Joan O. Weiss in 1986 and is headquartered in Washington, DC.

Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA.

Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT.

Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA.

Neurona Therapeutics, Inc. operates as a pre-clinical stage biotechnology company. It focuses on the discovery and development of cell-based therapies to treat intractable neurological disease. The company was founded by Arnold R. Kriegstein, John Rubenstein, Cory R. Nicholas, and Arturo Alvarez-Buylla and is headquartered in South San Francisco, CA.

hC Bioscience, Inc. is a biotech company based in Cambridge, MA and has subsidiaries in the United States. A single trna therapy has the potential to treat many diseases, regardless of the gene or location of the mutation. hC Bioscience is dedicated to improving the lives of patients by developing first-in-class trna-based therapeutics that target protein dysfunction. The company's innovative approach to precision protein editing has the potential to treat genetically defined conditions that account for 10-15% of all human diseases. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). The company was founded in 2021 by Leslie J. Williams, who has been the CEO since then.

Global Genes is a non-profit organization that connects, empowers, and inspires the rare disease community to become more effective on their own behalf. The non-profit company is based in Aliso Viejo, CA and has subsidiaries in the United States. The company serve more than 400 million people around the globe and nearly one in 10 Americans affected by rare diseases. The organization helps spur innovation, meet essential needs, build capacity and knowledge, and drive progress within and across rare diseases. Global Genes was founded in 2008 and the CEO is Craig Martin.

Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA.

The Sidney Kimmel Comprehensive Cancer Center offers immune-based treatments for cancer. The company was founded by Sidney Kimmel in 1973 and is headquartered in Baltimore, MD.